Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2
Trial details
- Registry ID
- NCT04229979
- Phase
- Phase 3
The FDA approved Decitabine on 2 May 2006.
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2NCT04229979 | Sellas Life Sciences Group | Phase 3 | Active not recruiting | 2025-12Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2006-05-02Day | Decitabine | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA021790", "applicant_as_listed_by_fda": "OTSUKA", "brand_names": ["DACOGEN"], "active_ingredients": ["DECITABINE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20060502", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |